Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $30,080.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Zhenyu Xu sold 4,000 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $7.52, for a total value of $30,080.00. Following the transaction, the insider owned 586,887 shares of the company’s stock, valued at approximately $4,413,390.24. This trade represents a 0.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zhenyu Xu also recently made the following trade(s):

• On Friday, August 7th, Zhenyu Xu sold 17,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.29, for a total transaction of $123,930.00.
• On Wednesday, August 5th, Zhenyu Xu sold 3,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.00, for a total transaction of $21,000.00.
• On Tuesday, August 4th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.92, for a total transaction of $69,200.00.
• On Monday, July 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total transaction of $22,800.00.
• On Monday, July 6th, Zhenyu Xu sold 7,393 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.17, for a total transaction of $38,221.81.

SOPHiA GENETICS Price Performance

Shares of SOPHiA GENETICS stock opened at $7.50 on Monday. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. The company has a market cap of $629.17 million, a PE ratio of -6.52 and a beta of 0.96. The firm has a fifty day moving average price of $5.89 and a two-hundred day moving average price of $5.22. SOPHiA GENETICS SA has a fifty-two week low of $3.10 and a fifty-two week high of $7.88.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The company had revenue of $23.31 million for the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. Analysts expect that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on SOPH shares. HC Wainwright boosted their price target on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Finally, BTIG Research lifted their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $10.00.

Hedge Funds Weigh In On SOPHiA GENETICS

Hedge funds have recently made changes to their positions in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of SOPHiA GENETICS by 246.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after acquiring an additional 5,432,871 shares in the last quarter. Federated Hermes Inc. raised its position in SOPHiA GENETICS by 16.4% in the second quarter. Federated Hermes Inc. now owns 220,000 shares of the company’s stock worth $682,000 after purchasing an additional 31,000 shares in the last quarter. Akre Capital Management LLC raised its position in SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after purchasing an additional 1,481,636 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in SOPHiA GENETICS by 24.7% during the third quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after purchasing an additional 6,205 shares during the period. Finally, Squarepoint Ops LLC acquired a new stake in SOPHiA GENETICS during the third quarter valued at approximately $49,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.